Palmoplantar psoriasis can severely impact patient quality of life. Despite the influx of many new medications, it remains one of the most challenging psoriasis phenotypes to treat.
Case Description:
Herein, we present a case series of 7 patients with hyperkeratotic palmoplantar psoriasis refractory to systemic therapy who were successfully treated with tofacitinib, a Janus kinase (JAK) 1/3 inhibitor.
Conclusions:
Tofacitinib may be an effective therapy for the management of recalcitrant palmoplantar psoriasis. The efficacy of tofacitinib for the treatment of palmoplantar psoriasis might clarify the dependence on this subtype of psoriasis on specific cytokines that signal through JAK 1/3.
FarleyEMasrourSMcKeyJMenterA. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–1031.
2.
RaposoITorresT. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349–358.
3.
HaynesDTophamCHagstromEGreilingT. Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: a case report. Australas J Dermatol. 2019;61(1):e108–e110.
4.
MössnerRHoffPMohrJWilsmann-TheisD. Successful therapy of palmoplantar pustulosis with tofacitinib-report on three cases. Dermatol Ther. 2020;33(4):e13753.
DamskyWKingBA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
7.
Di LerniaVBardazziF. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016;10:533–539. doi:10.2147/DDDT.S82599
8.
HaoJQ. Targeting interleukin-22 in psoriasis. Inflammation. 2014;37(1):94–99. doi:10.1007/s10753-013-9715-y
BerekmeriAMahmoodFWittmannMHelliwellP. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730.
11.
TianFChenZXuT. Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. J Int Med Res. 2019;47(6):2342–2350.
12.
PappKAMenterMAAbeM, et al.Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961. doi:10.1111/bjd.14018
13.
PetteyAABalkrishnanRRappSRFleischerABFeldmanSR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271–275.
